A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without VX-970 in Metastatic Urothelial Carcinoma

Trial Profile

A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without VX-970 in Metastatic Urothelial Carcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs M 6620 (Primary) ; Cisplatin; Gemcitabine
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Sep 2016 Status changed from suspended to recruiting.
    • 22 Aug 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Aug 2018.
    • 22 Aug 2016 Status changed from not yet recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top